Journal: NPJ Vaccines
Article Title: Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach
doi: 10.1038/s41541-024-01014-8
Figure Lengend Snippet: Whole inactivated virus (WIV) with beta-propiolactone (BPL) and inactivated split vaccine combining BPL inactivation and Triton X-100 splitting were compared for two different vaccinations with WT viruses or mHA viruses. Vaccines were tested without adjuvant or with the addition of CpG 1018 (30 µg) as explained in Fig. . A Heatmap of IgG binding serum antibodies against a panel of recombinant influenza B HA proteins. B Heatmap of hemagglutination inhibition (HI) titer against a panel of influenza B viruses. C Heatmap of ADCC activity against three influenza B viruses. To perform the ADCC reporter assay, MDCK cells were infected with each virus at an MOI of 5 (single-cycle replication). One day after infection, mouse sera were added to the cells and incubated for 30 min and genetically modified Jurkat cells expressing the mouse FcγRIV with a luciferase reporter gene under transcriptional control of the nuclear factor-activated T (NFAT) cell promoter were then added and incubated for 6 h. Later luciferase activity was measured. The geometric mean AUC of fold induction of each group (pooled sera) was measured in technical duplicate.
Article Snippet: Genetically modified Jurkat cells expressing the mouse FcγRIV with a luciferase reporter gene under transcriptional control of the nuclear factor-activated T (NFAT) cell promoter were then added to the plate at 7.5× 10 4 cells in 25 μL/well (Promega) and incubated for 6 hours at 37 °C.
Techniques: Virus, Vaccines, Adjuvant, Binding Assay, Recombinant, HI Assay, Activity Assay, Reporter Assay, Infection, Incubation, Genetically Modified, Expressing, Luciferase, Control
